Los Angeles & Oceanside, CA, December 7, 2006--- Lifeline Cell Technology, an International Stem Cell Corporation (ISC) company (www.intlstemcell.com), will showcase its new product line of human origin specialized cells and cell growth media to cell biology scientists at the 46th Annual American Society for Cell Biology Conference (www.ascb.org) scheduled for December 9-13, 2006 in San Diego.
The line of Lifeline products includes: standardized human "feeder" cells (called "fibroblasts") and specialized animal-free growth medium, a system that can provide feeder layers to grow and maintain human embryonic stem cells without contamination from animal cells (sold under the name FibroLife™); a kit containing human blood-vessel cells and growth media (sold under the name "VascuLife™) for the study of cardiovascular diseases; and a unique line of adult nerve cells and nerve stem cells with the ability to survive in low-oxygen conditions, for research into stroke.
According to Jeffrey Janus, Co-founder and CEO of Lifeline Cell Technology and President of International Stem Cell Corporation, "these products offer effective tools for researchers to advance the therapeutic use of stem cells for regenerative medicine and drug discovery."
Jeff Krstich, CEO of ISC says, "ISC is focused on the therapeutic use of stem cells. We are applying Lifeline's technologies toward the development of animal free cells and media for the treatment of retinal disease, diabetes and liver disease. We are pleased with the launch of these Lifeline products because they provide additional financial stability and help us establish relationships with leading researchers in the field of stem cell therapy."
Lifeline has begun sales and distribution to academic, commercial and U.S. government researchers in related fields of human therapeutic stem cell transplantation. The products have been sold to such entities as the National Institutes of Health, the US Army and leading academic research laboratories in the field.
Janus, who prior to co-founding Lifeline pioneered the development and commercialization of human cell products, including products that have since moved into clinical testing, added that "historically, stem cell research has been done with layers of mouse feeder cells and media containing animal components."
"Using human cells without animal cell contamination is more appropriate," he continued, "because it is more likely that in such an environment human cells will act more appropriately to the human condition and will be more acceptable for human trials." Lifeline also has the resources to produce customized feeder cells and growth media to meet specific demands of researchers.
The American Society for Cell Biology (ASCB) was founded in 1960 to bring the varied facets of cell biology together. The Society's purpose is to promote and develop the field of cell biology. Membership in the ASCB is open to all scientists who have education or research experience in cell biology or an allied field.
About Lifeline Cell Technology and International Stem Cell Corporation (ISC) With research and product development facilities in Oceanside CA, Walkersville, MD and Moscow, Russia, ISC's mission is to bring to market therapeutic-grade human cells, derived from unfertilized human eggs, to treat human degenerative diseases using embryonic stem cell technologies. ISC's initial focus is on the treatment of diabetes, liver and retinal diseases. It also has developed, produces and markets under Lifeline Cell Technology, a line of products for research that includes serum-free growth media and reagents essential to the process of creating and differentiating stem cells into therapeutic products. Visit ISC's website at www.internationalstemcell.com.
Disclosures:
Lifeline Cell Technology products are for research use only, not for use in therapeutic or diagnostic procedures.
Safe Harbor Statement
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the Act). Investors are cautioned that such forward-looking statements regarding the company, its technology, clinical development and potential applications, constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. International Stem Cell Corporation disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act.
|